Other agents targeting dopaminergic pathways (i.e., dopaminergic agonists, monoamine oxidase B (MAO-B), selegiline, and rasagiline) can positively affect dopaminergic neurotransmission, thus ameliorating PD-related symptoms [18]. Here, MAOB is linked to Parkinson disease.